Table 1

Participant demographics at study enrolment by vaccine type. Participant characteristics at baseline are presented overall and compared across vaccine groups, using either the χ2 test for categorical variables or Kruskal-Wallis test for continuous variables.

Vaccine typeP value
Total
(N=6943)
Pfizer-BioNTech
(N=3824)
Moderna
(N=2620)
Adenoviral Vector/mRNA
(N=499)
Age at enrolment (median, IQR)64 (53–75)71 (55–78)61 (54–69)45 (31–55).
Age group (N, %)<0.0001
 18–25159 (2.3)59 (1.5)64 (2.4)36 (7.2).
 25–39384 (5.5)152 (4.0)62 (2.4)170 (34.1).
 40–643191 (46.0)1326 (34.7)1577 (60.2)288 (57.7).
 65–792313 (33.3)1557 (40.7)752 (28.7)4 (0.8).
 ≥80896 (12.9)730 (19.1)165 (6.3)1 (0.2).
Sex (N, %)<0.0001
 Male3014 (43.4)1841 (48.1)1085 (41.4)88 (17.6).
 Female3929 (56.6)1983 (51.9)1535 (58.6)411 (82.4).
Risk group (N,%)<0.0001
 Individuals at increased risk1599 (23.0)1437 (37.6)153 (5.8)9 (1.8).
 Healthcare workers590 (8.5)109 (2.9)28 (1.1)453 (90.8).
 General population4754 (68.5)2278 (59.6)2439 (93.1)37 (7.4).
Ever SARS-CoV-2 PCR positive<0.0001
Never6704 (96.6)3718 (97.2)2534 (96.7)452 (90.6).
Positive ≤6 months180 (2.6)82 (2.1)56 (2.1)42 (8.4).
Positive >6 months59 (0.8)24 (0.6)30 (1.1)5 (1.0).